NL7013068A
(pt)
|
1969-09-17 |
1971-03-19 |
|
|
US4537889A
(en)
|
1982-12-27 |
1985-08-27 |
Eli Lilly And Company |
Inotropic agents
|
US4614810A
(en)
|
1984-09-24 |
1986-09-30 |
Pennwalt Corporation |
4,5-dihydro-4-oxo-2-[(2-trans-phenylcyclopropyl)amino]-3-furancarboxylic acids and derivatives thereof
|
US4625040A
(en)
|
1984-09-24 |
1986-11-25 |
Pennwalt Corporation |
N-(phenyl) or N-(phenylcyclopropyl)-2,5-dihydro-2-oxo-4[(substituted phenyl)amino]-3-furancarboxamide derivatives
|
FR2607813B1
(fr)
|
1986-12-05 |
1989-03-31 |
Montpellier I Universite |
Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique
|
JPH032778Y2
(pt)
|
1986-12-15 |
1991-01-24 |
|
|
AU622330B2
(en)
|
1989-06-23 |
1992-04-02 |
Takeda Chemical Industries Ltd. |
Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
|
JP2844351B2
(ja)
|
1989-07-13 |
1999-01-06 |
株式会社科薬 |
安定なポリミキシン系抗生物質水性溶液
|
IL96432A0
(en)
|
1989-11-30 |
1991-08-16 |
Schering Ag |
Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives
|
FR2662163A1
(fr)
|
1990-05-16 |
1991-11-22 |
Lipha |
Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant.
|
ATE177426T1
(de)
|
1992-06-17 |
1999-03-15 |
Upjohn Co |
Pyrridino-, pyrrolidino- und azepino- substituierte oxime als antiatherosklerosemittel und antihypercholesterolemiemittel
|
JP2923139B2
(ja)
|
1992-10-05 |
1999-07-26 |
三井化学株式会社 |
製 剤
|
DE4327027A1
(de)
|
1993-02-15 |
1994-08-18 |
Bayer Ag |
Imidazoazine
|
FR2711993B1
(fr)
|
1993-11-05 |
1995-12-01 |
Rhone Poulenc Rorer Sa |
Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation.
|
US5932223A
(en)
|
1996-09-26 |
1999-08-03 |
Merck & Co., Inc. |
Rotavirus vaccine formulations
|
KR20010031983A
(ko)
|
1997-11-11 |
2001-04-16 |
우에노 도시오 |
축합 피라진 화합물
|
JP2000319277A
(ja)
|
1999-05-11 |
2000-11-21 |
Ono Pharmaceut Co Ltd |
縮合ピラジン化合物およびその化合物を有効成分とする薬剤
|
JP2000319278A
(ja)
|
1999-05-11 |
2000-11-21 |
Ono Pharmaceut Co Ltd |
縮合ピラジン化合物およびその化合物を有効成分とする薬剤
|
JP4032566B2
(ja)
|
1999-06-21 |
2008-01-16 |
東レ株式会社 |
発光素子
|
JP4041624B2
(ja)
|
1999-07-21 |
2008-01-30 |
三井化学株式会社 |
有機電界発光素子
|
JP2001057292A
(ja)
|
1999-08-20 |
2001-02-27 |
Toray Ind Inc |
発光素子
|
RU2238087C2
(ru)
|
1999-09-28 |
2004-10-20 |
Панацея Биотек Лимитед |
Композиции контролируемого высвобождения, содержащие нимесулид
|
SE9903611D0
(sv)
|
1999-10-06 |
1999-10-06 |
Astra Ab |
Novel compounds III
|
DE19948434A1
(de)
|
1999-10-08 |
2001-06-07 |
Gruenenthal Gmbh |
Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
|
JP4409680B2
(ja)
|
1999-10-18 |
2010-02-03 |
株式会社ヤクルト本社 |
三環性縮合イミダゾール誘導体
|
CN1173975C
(zh)
|
2000-04-27 |
2004-11-03 |
山之内制药株式会社 |
咪唑并吡啶衍生物
|
US6403588B1
(en)
|
2000-04-27 |
2002-06-11 |
Yamanouchi Pharmaceutical Co., Ltd. |
Imidazopyridine derivatives
|
BR0111747A
(pt)
|
2000-06-28 |
2003-07-08 |
Smithkline Beecham Plc |
Processo de moagem úmida
|
AR029538A1
(es)
|
2000-07-06 |
2003-07-02 |
Wyeth Corp |
Composiciones farmaceuticas de agentes estrogenicos
|
CA2419626A1
(en)
|
2000-07-14 |
2002-01-24 |
Rajagopal Bakthavatachalam |
Imidazo¬1,2-a|pyrazines for the treatment of neurological disorders
|
DE10050663A1
(de)
|
2000-10-13 |
2002-04-18 |
Gruenenthal Gmbh |
Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
|
AU2001295992A1
(en)
|
2000-10-24 |
2002-05-06 |
Sankyo Company Limited |
Imidazopyridine derivatives
|
JP2002205992A
(ja)
|
2000-11-08 |
2002-07-23 |
Takeda Chem Ind Ltd |
二環式トリアゾロン誘導体およびそれを含有する除草剤
|
JP4302980B2
(ja)
|
2000-11-10 |
2009-07-29 |
メルク シャープ エンド ドーム リミテッド |
Gaba受容体リガンドとしてのイミダゾ−トリアジン誘導体
|
WO2002048146A2
(de)
|
2000-12-13 |
2002-06-20 |
Basf Aktiengesellschaft |
Verwendung von substituierten imidazoazinen, neue imidazoazine, verfahren zu deren herstellung, sowie sie enthaltende mittel
|
EP1217000A1
(en)
|
2000-12-23 |
2002-06-26 |
Aventis Pharma Deutschland GmbH |
Inhibitors of factor Xa and factor VIIa
|
TWI312347B
(en)
|
2001-02-08 |
2009-07-21 |
Eisai R&D Man Co Ltd |
Bicyclic nitrogen-containing condensed ring compounds
|
US6951848B2
(en)
|
2001-03-12 |
2005-10-04 |
Millennium Pharmaceuticals, Inc., |
Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
|
AR035543A1
(es)
|
2001-06-26 |
2004-06-16 |
Japan Tobacco Inc |
Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
|
IL159811A0
(en)
|
2001-07-13 |
2004-06-20 |
Neurogen Corp |
Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
|
US6921762B2
(en)
|
2001-11-16 |
2005-07-26 |
Amgen Inc. |
Substituted indolizine-like compounds and methods of use
|
WO2003062392A2
(en)
|
2002-01-18 |
2003-07-31 |
Ceretek Llc |
Methods of treating conditions associated with an edg receptor
|
US20050113283A1
(en)
|
2002-01-18 |
2005-05-26 |
David Solow-Cordero |
Methods of treating conditions associated with an EDG-4 receptor
|
AU2003255845A1
(en)
|
2002-08-22 |
2004-03-11 |
Piramed Limited |
Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
|
UA80296C2
(en)
|
2002-09-06 |
2007-09-10 |
Biogen Inc |
Imidazolopyridines and methods of making and using the same
|
AU2003304398A1
(en)
|
2002-10-16 |
2005-02-25 |
Board Of Regents, The University Of Texas System |
Methods and compositions for increasing the efficacy of biologically-active ingredients
|
AU2003297431A1
(en)
|
2002-12-20 |
2004-07-22 |
Pharmacia Corporation |
Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
|
WO2004072080A1
(en)
|
2003-02-10 |
2004-08-26 |
Cellular Genomics, Inc. |
Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of hsp90 complex activity
|
US7186832B2
(en)
|
2003-02-20 |
2007-03-06 |
Sugen Inc. |
Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
|
US7157460B2
(en)
|
2003-02-20 |
2007-01-02 |
Sugen Inc. |
Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
|
GB0303910D0
(en)
|
2003-02-20 |
2003-03-26 |
Merck Sharp & Dohme |
Therapeutic agents
|
EP1604981A4
(en)
|
2003-03-14 |
2008-12-24 |
Ono Pharmaceutical Co |
NITROGENIC HETEROCYCLIC DERIVATIVES AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE SUBSTANCE
|
JP2006522750A
(ja)
|
2003-04-11 |
2006-10-05 |
ノボ ノルディスク アクティーゼルスカブ |
代謝性症候群ならびに関連の疾患および障害を治療するために、11β−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤および抗高血圧剤を使用する併用療法
|
EP1615647B1
(en)
|
2003-04-11 |
2010-01-20 |
High Point Pharmaceuticals, LLC |
Pharmaceutical use of fused 1,2,4-triazoles
|
CA2522431A1
(en)
|
2003-04-24 |
2004-11-11 |
Merck & Co., Inc. |
Inhibitors of akt activity
|
SE0301653D0
(sv)
|
2003-06-05 |
2003-06-05 |
Astrazeneca Ab |
Novel compounds
|
EP2287166A3
(en)
|
2003-07-14 |
2011-06-22 |
Arena Pharmaceuticals, Inc. |
Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
|
US7538120B2
(en)
|
2003-09-03 |
2009-05-26 |
Array Biopharma Inc. |
Method of treating inflammatory diseases
|
WO2005025558A1
(en)
|
2003-09-12 |
2005-03-24 |
Applied Reserach Systems Ars Holding N.V. |
Sulfonamide derivatives for the treatment of diabetes
|
JP2005089352A
(ja)
|
2003-09-16 |
2005-04-07 |
Kissei Pharmaceut Co Ltd |
新規なイミダゾ[1,5−a]ピラジン誘導体、それを含有する医薬組成物およびそれらの用途
|
ES2288270T3
(es)
|
2003-10-10 |
2008-01-01 |
Pfizer Products Incorporated |
2h-(1,2,4)triazolo(4,3-a)pirazinas sustituidas como inhibidores de gsk-3.
|
US7419978B2
(en)
|
2003-10-22 |
2008-09-02 |
Bristol-Myers Squibb Company |
Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
|
EP1677791A4
(en)
|
2003-10-31 |
2007-08-15 |
Takeda Pharmaceutical |
NITROGENIC CONDENSED HETEROCYCLIC COMPOUNDS
|
US20080249154A1
(en)
|
2003-12-26 |
2008-10-09 |
Ono Pharmaceutical Co., Ltd. |
Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates
|
JPWO2005077948A1
(ja)
|
2004-02-16 |
2008-01-10 |
第一製薬株式会社 |
抗真菌作用複素環化合物
|
US7306631B2
(en)
|
2004-03-30 |
2007-12-11 |
The Procter & Gamble Company |
Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
|
WO2005103003A2
(en)
*
|
2004-04-26 |
2005-11-03 |
Pfizer Inc. |
Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors
|
ATE516019T1
(de)
|
2004-05-11 |
2011-07-15 |
Egalet Ltd |
Quellbare dosierform mit gellan-gummit
|
TW200612918A
(en)
|
2004-07-29 |
2006-05-01 |
Threshold Pharmaceuticals Inc |
Lonidamine analogs
|
CA2577648A1
(en)
|
2004-08-18 |
2006-02-23 |
Pharmacia & Upjohn Company Llc |
Triazolopyridine compounds useful for the treatment of inflammation
|
JP2008511669A
(ja)
|
2004-09-02 |
2008-04-17 |
スミスクライン ビーチャム コーポレーション |
化合物
|
EP1799680A2
(en)
|
2004-10-07 |
2007-06-27 |
Warner-Lambert Company LLC |
Triazolopyridine derivatives as antibacterial agents
|
US20090042820A1
(en)
|
2004-11-22 |
2009-02-12 |
Threshold Pharmaceuticals, Inc. |
Tubulin Binding Anti Cancer Agents And Prodrugs Thereof
|
EP1828184B1
(en)
|
2004-12-01 |
2009-09-16 |
Merck Serono SA |
[1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases
|
WO2006073938A2
(en)
|
2004-12-30 |
2006-07-13 |
East Carolina University |
Method for the synthesis of 3-substituted indolizine and benzoindolizine compounds
|
US7456289B2
(en)
|
2004-12-31 |
2008-11-25 |
National Health Research Institutes |
Anti-tumor compounds
|
BRPI0607456A2
(pt)
|
2005-02-22 |
2009-09-08 |
Pfizer |
derivados de oxindol como agonistas do receptor 5ht4
|
ITBO20050123A1
(it)
|
2005-03-07 |
2005-06-06 |
Alfa Wassermann Spa |
Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
|
US20070078135A1
(en)
|
2005-04-18 |
2007-04-05 |
Neurogen Corporation |
Substituted heteroaryl CB1 antagonists
|
US7579360B2
(en)
|
2005-06-09 |
2009-08-25 |
Bristol-Myers Squibb Company |
Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
US7572807B2
(en)
|
2005-06-09 |
2009-08-11 |
Bristol-Myers Squibb Company |
Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
|
DE602005023544D1
(de)
|
2005-06-09 |
2010-10-21 |
Oncalis Ag |
Angiogeneseinhibitoren
|
US7632837B2
(en)
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
US7572808B2
(en)
|
2005-06-17 |
2009-08-11 |
Bristol-Myers Squibb Company |
Triazolopyridine cannabinoid receptor 1 antagonists
|
US7452892B2
(en)
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
EP1928237A4
(en)
|
2005-09-02 |
2011-03-09 |
Abbott Lab |
NEW HETEROCYCLES BASED ON IMIDAZO
|
WO2007032936A2
(en)
|
2005-09-09 |
2007-03-22 |
Schering Corporation |
Azafused cyclin dependent kinase inhibitors
|
CN101370811A
(zh)
|
2005-11-10 |
2009-02-18 |
先灵公司 |
作为蛋白激酶抑制剂的咪唑并吡嗪化合物
|
CA2631233C
(en)
|
2005-11-28 |
2011-11-08 |
Marinus Pharmaceuticals |
Ganaxolone formulations and methods for the making and use thereof
|
ES2376357T3
(es)
|
2005-12-27 |
2012-03-13 |
F. Hoffmann-La Roche Ag |
Derivados de aril-isoxazol-4-il-imidazo[1,5-a]piridina.
|
WO2007074491A1
(en)
|
2005-12-28 |
2007-07-05 |
Universita Degli Studi Di Siena |
HETEROTRICYCLIC AMIDE DERIVATIVES AS NEUROKININ-l (NKl) RECEPTOR LIGANDS
|
PE20070978A1
(es)
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
CN101410397A
(zh)
|
2006-03-31 |
2009-04-15 |
诺瓦提斯公司 |
有机化合物
|
US20090175852A1
(en)
|
2006-06-06 |
2009-07-09 |
Schering Corporation |
Imidazopyrazines as protein kinase inhibitors
|
EP2029605A1
(en)
|
2006-06-06 |
2009-03-04 |
Schering Corporation |
Imidazopyrazines as protein kinase inhibitors
|
JP2009541323A
(ja)
|
2006-06-22 |
2009-11-26 |
マリンクロット インコーポレイテッド |
拡張された共役を有するピラジン誘導体およびその使用
|
US8115000B2
(en)
|
2006-06-22 |
2012-02-14 |
Mallinckrodt Llc |
Pyrazine derivatives and uses thereof in renal monitoring
|
US8022088B2
(en)
|
2006-06-29 |
2011-09-20 |
Schering Corporation |
Substituted bicyclic and tricyclic thrombin receptor antagonists
|
WO2008005423A1
(en)
|
2006-07-03 |
2008-01-10 |
Cambrex Charles City, Inc. |
Improved method of making sufentanil
|
WO2008005908A2
(en)
|
2006-07-07 |
2008-01-10 |
Forest Laboratories Holdings Limited |
Pyridoimidazole derivatives
|
PE20080403A1
(es)
|
2006-07-14 |
2008-04-25 |
Amgen Inc |
Derivados heterociclicos fusionados y metodos de uso
|
US8198448B2
(en)
|
2006-07-14 |
2012-06-12 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
WO2008011557A2
(en)
|
2006-07-20 |
2008-01-24 |
Borchardt Allen J |
Heteroaryl inhibitors of rho kinase
|
WO2008027812A2
(en)
|
2006-08-28 |
2008-03-06 |
Forest Laboratories Holdings Limited |
Imidazopyridine and imidazopyrimidine derivatives
|
DE102006041292A1
(de)
|
2006-09-01 |
2008-03-06 |
Henkel Kgaa |
Wasserstoffperoxid-Aktivierung mit N-Heterocyclen
|
WO2008037607A1
(de)
|
2006-09-25 |
2008-04-03 |
Basf Se |
Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen
|
EP2086973B1
(en)
|
2006-10-11 |
2012-01-25 |
Amgen Inc., |
Imidazo- and triazolo-pyridine compounds and methods of use therof
|
WO2008063910A2
(en)
|
2006-11-08 |
2008-05-29 |
Novavax, Inc. |
Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
|
WO2008056176A1
(en)
|
2006-11-10 |
2008-05-15 |
Scottish Biomedical Limited |
Pyrazolopyrimidines as phosphodiesterase inhibitors
|
MX2009005144A
(es)
|
2006-11-22 |
2009-05-27 |
Incyte Corp |
Imidazotriazinas e imidazopirimidinas como inhibidores de cinasa.
|
EP2086540B8
(en)
|
2006-12-01 |
2011-03-02 |
Galapagos N.V. |
Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases
|
EP2063867A2
(en)
|
2006-12-22 |
2009-06-03 |
Combinatorx, Incorporated |
Pharmaceutical compositions for treatment of parkinson's disease and related disorders
|
WO2008110523A1
(en)
|
2007-03-09 |
2008-09-18 |
Probiodrug Ag |
Imidazo [1,5-a] pyridine derivatives as inhibitors of glutaminyl cyclase
|
DE102007012645A1
(de)
|
2007-03-16 |
2008-09-18 |
Bayer Healthcare Ag |
Substituierte Imidazo- und Triazolopyrimidine
|
EP1972628A1
(en)
|
2007-03-21 |
2008-09-24 |
Schwarz Pharma Ag |
Indolizines and aza-analog derivatives thereof as CNS active compounds
|
ATE540037T1
(de)
|
2007-04-16 |
2012-01-15 |
Leo Pharma As |
Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten
|
EP2474549A1
(en)
|
2007-04-17 |
2012-07-11 |
Bristol-Myers Squibb Company |
Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type I inhibitors
|
EP2155747B1
(en)
|
2007-05-10 |
2012-10-24 |
GE Healthcare Limited |
Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors
|
AU2008254038B2
(en)
|
2007-05-21 |
2013-01-10 |
Toray Industries, Inc. |
Oral preparation comprising specific organic acid, and method for improvement in elution property and chemical stability of oral preparation
|
US8648069B2
(en)
|
2007-06-08 |
2014-02-11 |
Abbvie Inc. |
5-substituted indazoles as kinase inhibitors
|
RU2487873C2
(ru)
|
2007-06-08 |
2013-07-20 |
Эбботт Лэборетриз |
5-замещенные индазолы в качестве ингибиторов киназы
|
WO2008156614A2
(en)
|
2007-06-14 |
2008-12-24 |
Schering Corporation |
Imidazopyrazines as protein kinase inhibitors
|
CL2008001839A1
(es)
|
2007-06-21 |
2009-01-16 |
Incyte Holdings Corp |
Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
|
US20090004281A1
(en)
|
2007-06-26 |
2009-01-01 |
Biovail Laboratories International S.R.L. |
Multiparticulate osmotic delivery system
|
KR20100049073A
(ko)
|
2007-07-18 |
2010-05-11 |
노파르티스 아게 |
비시클릭 헤테로아릴 화합물 및 키나제 억제제로서의 그의 용도
|
BRPI0814874A2
(pt)
|
2007-07-31 |
2019-09-24 |
Schering Corp |
combinação de agente antimitótico e inibidor da aurora quinase como tratamento anticâncer.
|
WO2009017954A1
(en)
|
2007-08-01 |
2009-02-05 |
Phenomix Corporation |
Inhibitors of jak2 kinase
|
JP2010535773A
(ja)
|
2007-08-10 |
2010-11-25 |
グラクソスミスクライン エルエルシー |
ウイルス感染を治療するための窒素含有二環式化学物質
|
US20090047336A1
(en)
|
2007-08-17 |
2009-02-19 |
Hong Kong Baptist University |
novel formulation of dehydrated lipid vesicles for controlled release of active pharmaceutical ingredient via inhalation
|
FR2920090A1
(fr)
|
2007-08-24 |
2009-02-27 |
Oreal |
Composition tinctoriale comprenant une base d'oxydation aminopyrazolopyridine particuliere, un coupleur et un tensioactif particulier.
|
FR2920091A1
(fr)
|
2007-08-24 |
2009-02-27 |
Oreal |
Composition tinctoriale comprenant une base d'oxydation aminopyrazolopyridine, un coupleur et un polyol particulier.
|
KR20090022616A
(ko)
|
2007-08-31 |
2009-03-04 |
한올제약주식회사 |
베실산클로피도그렐 함유 경구투여용 약제
|
US8119658B2
(en)
|
2007-10-01 |
2012-02-21 |
Bristol-Myers Squibb Company |
Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
GB0719803D0
(en)
|
2007-10-10 |
2007-11-21 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
ES2522365T3
(es)
|
2007-10-11 |
2014-11-14 |
Astrazeneca Ab |
Derivados de pirrolo [2,3-D] pirimidina como inhibidores de proteína quinasas B
|
HUE027696T2
(en)
|
2007-10-12 |
2016-10-28 |
Novartis Ag |
Preparations containing sphingosine-1-phosphate (S1P) receptor modulators
|
AU2008343813B2
(en)
|
2007-12-19 |
2012-04-12 |
Amgen Inc. |
Inhibitors of PI3 kinase
|
PT2231662E
(pt)
|
2007-12-19 |
2011-09-12 |
Genentech Inc |
8-anilinoimidazopiridinas e o seu uso como agentes anticancerígenos e/ou anti-inflamatórios
|
KR100988233B1
(ko)
|
2007-12-26 |
2010-10-18 |
한미홀딩스 주식회사 |
클로피도그렐 1,5-나프탈렌 다이술폰산 염 또는 이의수화물의 약학 조성물 및 제제
|
NZ587928A
(en)
|
2008-03-11 |
2012-08-31 |
Incyte Corp |
Azetidine and cyclobutane derivatives as jak inhibitors
|
CA2718403A1
(en)
|
2008-03-13 |
2009-09-17 |
The General Hospital Corporation |
Inhibitors of the bmp signaling pathway
|
JP5547099B2
(ja)
|
2008-03-14 |
2014-07-09 |
インテリカイン, エルエルシー |
キナーゼ阻害剤および使用方法
|
US20110105457A1
(en)
|
2008-04-18 |
2011-05-05 |
Shionogi & Co., Ltd. |
Heterocyclic compound having inhibitory activity on pi3k
|
DE102008023801A1
(de)
|
2008-05-15 |
2009-11-19 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
|
US8349210B2
(en)
|
2008-06-27 |
2013-01-08 |
Transitions Optical, Inc. |
Mesogenic stabilizers
|
WO2010010188A1
(en)
|
2008-07-25 |
2010-01-28 |
Galapagos Nv |
Novel compounds useful for the treatment of degenerative and inflammatory diseases.
|
WO2010010187A1
(en)
|
2008-07-25 |
2010-01-28 |
Galapagos Nv |
Novel compounds useful for the treatment of degenerative and inflammatory diseases
|
WO2010010184A1
(en)
|
2008-07-25 |
2010-01-28 |
Galapagos Nv |
[1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
|
WO2010010189A1
(en)
|
2008-07-25 |
2010-01-28 |
Galapagos Nv |
Novel compounds useful for the treatment of degenerative and inflammatory diseases
|
UY32049A
(es)
|
2008-08-14 |
2010-03-26 |
Takeda Pharmaceutical |
Inhibidores de cmet
|
TR200806298A2
(tr)
|
2008-08-22 |
2010-03-22 |
Bi̇lgi̇ç Mahmut |
Farmasötik formülasyon
|
JP2010070503A
(ja)
|
2008-09-19 |
2010-04-02 |
Daiichi Sankyo Co Ltd |
抗真菌作用2−アミノトリアゾロピリジン誘導体
|
US20120021519A1
(en)
|
2008-09-19 |
2012-01-26 |
Presidents And Fellows Of Harvard College |
Efficient induction of pluripotent stem cells using small molecule compounds
|
CA2738429C
(en)
|
2008-09-26 |
2016-10-25 |
Intellikine, Inc. |
Heterocyclic kinase inhibitors
|
WO2010043721A1
(en)
|
2008-10-17 |
2010-04-22 |
Oryzon Genomics, S.A. |
Oxidase inhibitors and their use
|
WO2010048149A2
(en)
|
2008-10-20 |
2010-04-29 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
US20120010188A1
(en)
|
2008-12-04 |
2012-01-12 |
Promimagen Ltd. |
Imidazopyridine Compounds
|
US8450321B2
(en)
|
2008-12-08 |
2013-05-28 |
Gilead Connecticut, Inc. |
6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
|
WO2010084160A1
(en)
|
2009-01-21 |
2010-07-29 |
Oryzon Genomics S.A. |
Phenylcyclopropylamine derivatives and their medical use
|
WO2010090991A1
(en)
|
2009-02-04 |
2010-08-12 |
Supernus Pharmaceuticals, Inc. |
Formulations of desvenlafaxine
|
CA2750517A1
(en)
|
2009-02-04 |
2010-08-12 |
Vitae Pharmaceuticals, Inc. |
Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
|
TR200900878A2
(tr)
|
2009-02-05 |
2010-08-23 |
Bi̇lgi̇ç Mahmut |
Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar
|
TR200900879A2
(tr)
|
2009-02-05 |
2010-08-23 |
Bi̇lgi̇ç Mahmut |
Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler
|
CA2752114C
(en)
|
2009-02-13 |
2017-06-20 |
Bayer Pharma Aktiengesellschaft |
Fused pyrimidines as akt inhibitors
|
KR20100101055A
(ko)
|
2009-03-07 |
2010-09-16 |
주식회사 메디젠텍 |
세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동 관련 질환의 치료 또는 예방용 약학적 조성물
|
WO2010107404A1
(en)
|
2009-03-16 |
2010-09-23 |
Mahmut Bilgic |
Stable pharmaceutical combinations
|
AR076052A1
(es)
|
2009-03-20 |
2011-05-18 |
Incyte Corp |
Derivados de pirimidinas sustituidas, composiciones farmaceuticas que los contienen y uso de los mismos en trastornos asociados con receptores de histamina h4, tales como trastornos inflamatorios, prurito y dolor.
|
WO2010113942A1
(ja)
|
2009-03-31 |
2010-10-07 |
キッセイ薬品工業株式会社 |
インドリジン誘導体及びその医薬用途
|
CA2756759C
(en)
|
2009-04-16 |
2017-11-07 |
Joaquin Pastor Fernandez |
Imidazopyrazines for use as kinase inhibitors
|
TWI461426B
(zh)
|
2009-05-27 |
2014-11-21 |
Merck Sharp & Dohme |
(二氫)咪唑並異〔5,1-a〕喹啉類
|
CN102803268A
(zh)
|
2009-06-10 |
2012-11-28 |
桑诺维恩药品公司 |
组胺h3反相激动剂和拮抗剂及其使用方法
|
CA2766033C
(en)
|
2009-06-25 |
2016-09-20 |
Alkermes, Inc. |
Prodrugs of nh-acidic compounds
|
EP2467141B1
(en)
|
2009-08-17 |
2018-10-31 |
Intellikine, LLC |
Heterocyclic compounds and uses thereof
|
AU2010284221B2
(en)
|
2009-08-18 |
2016-09-22 |
Casero, Robert A |
(bis) urea and (bis) thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
|
WO2011033265A1
(en)
|
2009-09-18 |
2011-03-24 |
Almac Discovery Limited |
Pharmaceutical compounds
|
BR112012006572A2
(pt)
|
2009-09-25 |
2016-04-26 |
Oryzon Genomics Sa |
inibidores de demetilase-1 de lisina específicos e seu uso
|
WO2011042217A1
(en)
|
2009-10-09 |
2011-04-14 |
Oryzon Genomics S.A. |
Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
|
WO2011050245A1
(en)
|
2009-10-23 |
2011-04-28 |
Yangbo Feng |
Bicyclic heteroaryls as kinase inhibitors
|
US8541404B2
(en)
|
2009-11-09 |
2013-09-24 |
Elexopharm Gmbh |
Inhibitors of the human aldosterone synthase CYP11B2
|
US8614315B2
(en)
|
2009-12-25 |
2013-12-24 |
Mahmut Bilgic |
Cefdinir and cefixime formulations and uses thereof
|
CA2787714C
(en)
|
2010-01-22 |
2019-04-09 |
Joaquin Pastor Fernandez |
Inhibitors of pi3 kinase
|
WO2011097607A1
(en)
|
2010-02-08 |
2011-08-11 |
Southern Research Institute |
Anti-viral treatment and assay to screen for anti-viral agent
|
WO2011106105A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Inhibitors for antiviral use
|
WO2011106573A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
|
TW201200518A
(en)
|
2010-03-10 |
2012-01-01 |
Kalypsys Inc |
Heterocyclic inhibitors of histamine receptors for the treatment of disease
|
WO2011113862A1
(en)
|
2010-03-18 |
2011-09-22 |
Bayer Pharma Aktiengesellschaft |
Imidazopyrazines
|
AU2011229423B2
(en)
|
2010-03-18 |
2015-12-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Anti-infective compounds
|
EP2552920B1
(en)
|
2010-04-02 |
2017-03-15 |
Ogeda Sa |
Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders
|
US8722743B2
(en)
|
2010-04-19 |
2014-05-13 |
Oryzon Genomics S.A. |
Lysine specific demethylase-1 inhibitors and their use
|
PL2560949T3
(pl)
|
2010-04-20 |
2017-01-31 |
Università Degli Studi Di Roma "La Sapienza" |
Pochodne tranylocyprominy jako inhibitory demetylazy histonowej LSD1 i/lub LSD2
|
CN102770414A
(zh)
|
2010-04-28 |
2012-11-07 |
第一三共株式会社 |
[5,6]杂环化合物
|
NZ603876A
(en)
|
2010-05-13 |
2015-02-27 |
Amgen Inc |
Nitrogen heterocyclic compounds useful as pde10 inhibitors
|
WO2011141713A1
(en)
|
2010-05-13 |
2011-11-17 |
Centro Nacional De Investigaciones Oncologicas (Cnio) |
New bicyclic compounds as pi3-k and mtor inhibitors
|
CN102247321A
(zh)
|
2010-05-20 |
2011-11-23 |
上海亚盛医药科技有限公司 |
一种阿朴棉子酚酮自乳化药物传递系统及其制备方法
|
EP2575808A1
(en)
|
2010-05-28 |
2013-04-10 |
Mahmut Bilgic |
Combination of antihypertensive agents
|
CN102295642B
(zh)
|
2010-06-25 |
2016-04-06 |
中国人民解放军军事医学科学院毒物药物研究所 |
2-芳基咪唑并[1,2-a]吡啶-3-乙酰胺衍生物、其制备方法及用途
|
WO2012003392A1
(en)
|
2010-07-02 |
2012-01-05 |
Gilead Sciences, Inc. |
Fused heterocyclic compounds as ion channel modulators
|
CN103097384B
(zh)
|
2010-07-12 |
2017-02-15 |
拜耳知识产权有限责任公司 |
取代的咪唑并[1,2‑a]嘧啶和吡啶
|
WO2012009475A1
(en)
|
2010-07-14 |
2012-01-19 |
Oregon Health & Science University |
Methods of treating cancer with inhibition of lysine-specific demethylase 1
|
CN101987082B
(zh)
|
2010-07-16 |
2013-04-03 |
钟术光 |
固体制剂及其制备方法
|
CN101987081B
(zh)
|
2010-07-16 |
2012-08-08 |
钟术光 |
一种控释制剂
|
WO2012016133A2
(en)
|
2010-07-29 |
2012-02-02 |
President And Fellows Of Harvard College |
Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
|
US9006449B2
(en)
|
2010-07-29 |
2015-04-14 |
Oryzon Genomics, S.A. |
Cyclopropylamine derivatives useful as LSD1 inhibitors
|
HUE037937T2
(hu)
|
2010-07-29 |
2021-11-29 |
Oryzon Genomics Sa |
Arilciklopropilamin-alapú LSD1-demetiláz inhibitorok és gyógyászati alkalmazásuk
|
CN102397552B
(zh)
|
2010-09-10 |
2016-06-08 |
广州自远生物科技有限公司 |
一种含喹诺酮类的药物复合制剂及其制备方法和应用
|
US9527805B2
(en)
|
2010-09-10 |
2016-12-27 |
Robert A. Casero |
Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
|
US9643969B2
(en)
|
2010-09-29 |
2017-05-09 |
Kissei Pharmaceutical Co., Ltd. |
(aza)indolizine derivative and pharmaceutical use thereof
|
US20130303545A1
(en)
|
2010-09-30 |
2013-11-14 |
Tamara Maes |
Cyclopropylamine derivatives useful as lsd1 inhibitors
|
JP2013540767A
(ja)
|
2010-10-07 |
2013-11-07 |
ザ ジェイ. デヴィッド グラッドストーン インスティテューツ |
免疫不全ウイルス転写を調節するための組成物および方法
|
KR101941300B1
(ko)
|
2010-10-18 |
2019-01-22 |
이 아이 듀폰 디 네모아 앤드 캄파니 |
살선충성 설폰아미드
|
KR20140009181A
(ko)
|
2010-10-21 |
2014-01-22 |
바이오마린 파머수티컬 인크. |
결정질의 (8s,9r)-5-플루오로-8-(4-플루오로페닐)-9-(1-메틸-1h-1,2,4-트리아졸-5-일)-8,9-디하이드로-2h-피리도[4,3,2-de]프탈라진-3(7h)-온 토실레이트 염
|
WO2012052745A1
(en)
|
2010-10-21 |
2012-04-26 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
Combinations of pi3k inhibitors with a second anti -tumor agent
|
EP2444084A1
(en)
|
2010-10-21 |
2012-04-25 |
Centro Nacional de Investigaciones Oncológicas (CNIO) |
Use of PI3K inibitors for the treatment of obesity
|
WO2012071469A2
(en)
|
2010-11-23 |
2012-05-31 |
Nevada Cancer Institute |
Histone demethylase inhibitors and uses thereof for treatment o f cancer
|
WO2012072713A2
(en)
|
2010-11-30 |
2012-06-07 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
|
EP2651405A2
(en)
|
2010-12-14 |
2013-10-23 |
Electrophoretics Limited |
Casein kinase 1 (ck1 ) inhibitors
|
UY33805A
(es)
|
2010-12-17 |
2012-07-31 |
Boehringer Ingelheim Int |
?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?.
|
CA2821834A1
(en)
|
2010-12-17 |
2012-06-21 |
Bayer Intellectual Property Gmbh |
6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
|
CA2821819A1
(en)
|
2010-12-17 |
2012-06-21 |
Marcus Koppitz |
6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
|
ES2556458T3
(es)
|
2010-12-17 |
2016-01-18 |
Bayer Intellectual Property Gmbh |
6-Imidazopirazinas sustituidas para uso como inhibidores de Mps-1 y TKK en el tratamiento de trastornos hiperproliferativos
|
WO2012080232A1
(en)
|
2010-12-17 |
2012-06-21 |
Bayer Pharma Aktiengesellschaft |
2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
|
TWI617559B
(zh)
|
2010-12-22 |
2018-03-11 |
江蘇恆瑞醫藥股份有限公司 |
2-芳基咪唑并[1,2-b]嗒.2-苯基咪唑并[1,2-a]吡啶,和2-苯基咪唑并[1,2-a]吡衍生物
|
EP2655334B1
(en)
|
2010-12-22 |
2018-10-03 |
Eutropics Pharmaceuticals, Inc. |
Compositions and methods useful for treating diseases
|
EP2665726A4
(en)
|
2011-01-21 |
2014-09-03 |
Gen Hospital Corp |
COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES
|
EP2712315B1
(en)
|
2011-02-08 |
2021-11-24 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for myeloproliferative disorders
|
US20140163041A1
(en)
|
2011-02-08 |
2014-06-12 |
Oryzon Genomics S.A. |
Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
|
EP2678016B1
(en)
|
2011-02-23 |
2016-08-10 |
Intellikine, LLC |
Heterocyclic compounds and uses thereof
|
WO2012129562A2
(en)
|
2011-03-24 |
2012-09-27 |
The Scripps Research Institute |
Compounds and methods for inducing chondrogenesis
|
WO2012135113A2
(en)
|
2011-03-25 |
2012-10-04 |
Glaxosmithkline Llc |
Cyclopropylamines as lsd1 inhibitors
|
WO2012147890A1
(ja)
|
2011-04-27 |
2012-11-01 |
持田製薬株式会社 |
新規アゾール誘導体
|
EP2524918A1
(en)
|
2011-05-19 |
2012-11-21 |
Centro Nacional de Investigaciones Oncológicas (CNIO) |
Imidazopyrazines derivates as kinase inhibitors
|
US20140296255A1
(en)
|
2011-05-19 |
2014-10-02 |
Oryzong Genomics, S.A. |
Lysine demethylase inhibitors for thrombosis and cardiovascular diseases
|
WO2012156531A2
(en)
|
2011-05-19 |
2012-11-22 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for inflammatory diseases or conditions
|
WO2012168882A1
(en)
|
2011-06-07 |
2012-12-13 |
SPAI Group Ltd. |
Compositions and methods for improving stability and extending shelf life of sensitive food additives and food products thereof
|
AU2012273164B2
(en)
|
2011-06-20 |
2015-05-28 |
Incyte Holdings Corporation |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
|
TW201311149A
(zh)
|
2011-06-24 |
2013-03-16 |
Ishihara Sangyo Kaisha |
有害生物防治劑
|
EP2548877A1
(en)
|
2011-07-19 |
2013-01-23 |
MSD Oss B.V. |
4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
|
CA2844525A1
(en)
*
|
2011-08-09 |
2013-02-14 |
Takeda Pharmaceutical Company Limited |
Cyclopropaneamine compound
|
WO2013025805A1
(en)
|
2011-08-15 |
2013-02-21 |
University Of Utah Research Foundation |
Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors
|
US9289415B2
(en)
|
2011-09-01 |
2016-03-22 |
The Brigham And Women's Hospital, Inc. |
Treatment of cancer
|
WO2013033515A1
(en)
|
2011-09-02 |
2013-03-07 |
Promega Corporation |
Compounds and methods for assaying redox state of metabolically active cells and methods for measuring nad(p)/nad(p)h
|
CN106905324B
(zh)
|
2011-10-10 |
2018-09-25 |
H.隆德贝克有限公司 |
具有咪唑并吡嗪酮骨架的pde9抑制剂
|
SI2776394T1
(sl)
*
|
2011-10-20 |
2019-05-31 |
Oryzon Genomics, S.A. |
Spojine (hetero)aril ciklopropilamina kot inhibitorji LSD1
|
CL2014000988A1
(es)
|
2011-10-20 |
2014-11-03 |
Oryzon Genomics Sa |
Compuestos derivados de (aril o heteroaril) ciclopropilamida, inhibidores de lsd1; procedimiento para prepararlos; composicion farmaceutica que los comprende; y metodo para tratar o prevenir cancer, una enfermedad neurologica, una infeccion viral y la reactivacion viral despues de la latencia.
|
KR102139537B1
(ko)
*
|
2011-10-20 |
2020-07-31 |
오리존 지노믹스 에스.에이. |
Lsd1 억제제로서 (헤테로)아릴 사이클로프로필아민 화합물
|
ITMI20111971A1
(it)
|
2011-10-28 |
2013-04-29 |
Mesogenics Srl |
Inibitori dell'enzima lsd-1 per l'induzione del differenziamento osteogenico
|
WO2013074390A1
(en)
|
2011-11-14 |
2013-05-23 |
Merck Sharp & Dohme Corp. |
Triazolopyridinone pde10 inhibitors
|
US20140288145A1
(en)
|
2011-12-05 |
2014-09-25 |
Brandeis University |
Treatment of amyloidosis by compounds that regulate retromer stabilization
|
CN104159901B
(zh)
|
2012-03-07 |
2016-10-26 |
默克专利股份公司 |
三唑并吡嗪衍生物
|
CN102587054B
(zh)
|
2012-03-13 |
2014-05-07 |
机械科学研究总院先进制造技术研究中心 |
缸盖自动锁紧装置及包括该装置的筒子纱染色机
|
CN102579381B
(zh)
|
2012-03-30 |
2013-07-10 |
河南中帅医药科技发展有限公司 |
盐酸胍法辛缓释制剂及其制备方法
|
GB201205669D0
(en)
|
2012-03-30 |
2012-05-16 |
Agency Science Tech & Res |
Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
|
CN103373996A
(zh)
|
2012-04-20 |
2013-10-30 |
山东亨利医药科技有限责任公司 |
作为crth2受体拮抗剂的二并环衍生物
|
WO2014002051A2
(en)
|
2012-06-28 |
2014-01-03 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
CN102772444A
(zh)
|
2012-07-06 |
2012-11-14 |
周明千 |
中药超微破壁口服片剂饮片的加工方法
|
GB201212513D0
(en)
|
2012-07-13 |
2012-08-29 |
Ucb Pharma Sa |
Therapeutic agents
|
SG11201503299YA
(en)
|
2012-09-28 |
2015-06-29 |
Univ Vanderbilt |
Fused heterocyclic compounds as selective bmp inhibitors
|
JP6457942B2
(ja)
|
2012-10-05 |
2019-01-23 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
Gdf−8阻害剤
|
EP2907802B1
(en)
*
|
2012-10-12 |
2019-08-07 |
Takeda Pharmaceutical Company Limited |
Cyclopropanamine compound and use thereof
|
WO2014078479A2
(en)
|
2012-11-14 |
2014-05-22 |
The Board Of Regents Of The University Of Texas System |
INHIBITION OF HIF-2α HETERODIMERIZATION WITH HIF1β (ARNT)
|
US9388123B2
(en)
|
2012-11-28 |
2016-07-12 |
Kyoto University |
LSD1-selective inhibitor having lysine structure
|
CA2892375A1
(en)
|
2012-11-30 |
2014-06-05 |
Darlene E. MCCORD |
Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition
|
EP2740474A1
(en)
|
2012-12-05 |
2014-06-11 |
Instituto Europeo di Oncologia S.r.l. |
Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
|
JP6111475B2
(ja)
|
2012-12-19 |
2017-04-12 |
ウォックハート リミテッド |
ヒトインスリン又はその類似体もしくは誘導体を含む安定な水性組成物
|
CN103054869A
(zh)
|
2013-01-18 |
2013-04-24 |
郑州大学 |
含三唑基的氨基二硫代甲酸酯化合物在制备以lsd1为靶标药物中的应用
|
CN103933036B
(zh)
|
2013-01-23 |
2017-10-13 |
中国人民解放军军事医学科学院毒物药物研究所 |
2‑芳基咪唑并[1,2‑α]吡啶‑3‑乙酰胺衍生物在制备防治PTSD的药物中的用途
|
EP2956441A4
(en)
|
2013-02-18 |
2016-11-02 |
Scripps Research Inst |
MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL
|
US8558008B2
(en)
|
2013-02-28 |
2013-10-15 |
Dermira, Inc. |
Crystalline glycopyrrolate tosylate
|
WO2014164867A1
(en)
|
2013-03-11 |
2014-10-09 |
Imago Biosciences |
Kdm1a inhibitors for the treatment of disease
|
EP2971007A4
(en)
|
2013-03-13 |
2017-03-22 |
Australian Nuclear Science And Technology Organisation |
Transgenic non-human organisms with non-functional tspo genes
|
JP2016517434A
(ja)
|
2013-03-14 |
2016-06-16 |
エピザイム,インコーポレイティド |
癌を処置するための併用療法
|
US20140343118A1
(en)
|
2013-03-14 |
2014-11-20 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
US9918983B2
(en)
|
2013-05-30 |
2018-03-20 |
The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas |
Suicidal LSD1 inhibitors targeting SOX2-expressing cancer cells
|
JP6525162B2
(ja)
|
2013-06-19 |
2019-06-05 |
ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション |
ヒストン脱メチル化酵素阻害剤としての置換(e)−n’−(1−フェニルエチリデン)ベンゾヒドラジド類似体
|
PE20160208A1
(es)
|
2013-06-21 |
2016-05-04 |
Myokardia Inc |
Compuestos de pirimidinodiona contra estados cardiacos
|
US9186391B2
(en)
|
2013-08-29 |
2015-11-17 |
Musc Foundation For Research Development |
Cyclic peptide inhibitors of lysine-specific demethylase 1
|
US9556170B2
(en)
|
2013-08-30 |
2017-01-31 |
University Of Utah Research Foundation |
Substituted-1H-benzo[d]imidazole series compounds as lysine-specific demethylase 1 (LSD1) inhibitors
|
US9770514B2
(en)
|
2013-09-03 |
2017-09-26 |
ExxPharma Therapeutics LLC |
Tamper-resistant pharmaceutical dosage forms
|
CN105658209A
(zh)
|
2013-09-13 |
2016-06-08 |
拜耳制药股份公司 |
含有瑞法美替的药物组合物
|
KR101568724B1
(ko)
|
2013-11-13 |
2015-11-12 |
서울대학교산학협력단 |
신규한 화합물, 이의 생산 방법, 및 히스톤 디메틸라제 저해제로서 이의 용도
|
FI3080100T3
(fi)
|
2013-12-11 |
2023-03-15 |
Celgene Quanticel Res Inc |
Lysiinispesifisen demetylaasi-1:n estäjät
|
HUE046273T2
(hu)
|
2014-02-13 |
2020-02-28 |
Incyte Corp |
Ciklopropilaminok mint LSD1 inhibitorok
|
US9493442B2
(en)
|
2014-02-13 |
2016-11-15 |
Incyte Corporation |
Cyclopropylamines as LSD1 inhibitors
|
US9346776B2
(en)
|
2014-02-13 |
2016-05-24 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic compound
|
CR20200362A
(es)
|
2014-02-13 |
2020-10-26 |
Incyte Corp |
CICLOPROPILAMINA COMO INHIBIDORES DE LA LSD1 (Divisional 2016-0395)
|
US9527835B2
(en)
|
2014-02-13 |
2016-12-27 |
Incyte Corporation |
Cyclopropylamines as LSD1 inhibitors
|
US9428470B2
(en)
|
2014-02-13 |
2016-08-30 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
CN103893163B
(zh)
|
2014-03-28 |
2016-02-03 |
中国药科大学 |
2-([1,1′-联苯]-4-基)2-氧代乙基4-((3-氯-4-甲基苯基)氨基)-4-氧代丁酸酯在制备lsd1抑制剂药物中的应用
|
MX2016012829A
(es)
|
2014-04-02 |
2017-01-05 |
Bristol Myers Squibb Co |
Inhibidores de biaril cinasa.
|
US10130618B2
(en)
|
2014-04-11 |
2018-11-20 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Pharmaceutical combinations of dabigatran and proton pump inhibitors
|
EP3129369A1
(en)
|
2014-04-11 |
2017-02-15 |
Takeda Pharmaceutical Company Limited |
Cyclopropanamine compound and use thereof
|
WO2015155297A1
(en)
|
2014-04-11 |
2015-10-15 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Pharmaceutical combinations of dabigatran and h2-receptor antagonists
|
CN103961340B
(zh)
|
2014-04-30 |
2019-06-25 |
南通中国科学院海洋研究所海洋科学与技术研究发展中心 |
一类lsd1抑制剂及其应用
|
WO2015181380A1
(en)
|
2014-05-30 |
2015-12-03 |
Ieo - Istituto Europeo Di Oncologia S.R.L. |
Cyclopropylamine compounds as histone demethylase inhibitors
|
CN104119280B
(zh)
|
2014-06-27 |
2016-03-16 |
郑州大学 |
含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用
|
US9695167B2
(en)
|
2014-07-10 |
2017-07-04 |
Incyte Corporation |
Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
|
US9695168B2
(en)
|
2014-07-10 |
2017-07-04 |
Incyte Corporation |
Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
|
US9758523B2
(en)
|
2014-07-10 |
2017-09-12 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as LSD1 inhibitors
|
TW201613925A
(en)
|
2014-07-10 |
2016-04-16 |
Incyte Corp |
Imidazopyrazines as LSD1 inhibitors
|
GB201417828D0
(en)
|
2014-10-08 |
2014-11-19 |
Cereno Scient Ab |
New methods and compositions
|
CN104173313B
(zh)
|
2014-08-25 |
2017-05-17 |
杭州朱养心药业有限公司 |
利伐沙班片剂药物组合物
|
JP6653116B2
(ja)
|
2014-08-27 |
2020-02-26 |
日本ケミファ株式会社 |
オルメサルタンのプロドラッグ製剤
|
KR102550852B1
(ko)
|
2014-10-08 |
2023-07-05 |
에프. 호프만-라 로슈 아게 |
알도스테론 신타아제 억제제로서의 스피로다이아민 유도체
|
US10399932B2
(en)
|
2015-04-03 |
2019-09-03 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer
|
US9944647B2
(en)
|
2015-04-03 |
2018-04-17 |
Incyte Corporation |
Heterocyclic compounds as LSD1 inhibitors
|
BR112017020935A2
(pt)
|
2015-04-03 |
2018-07-10 |
Mutabilis |
?compostos, composição farmacêutica e conjunto?
|
JP7427363B2
(ja)
|
2015-08-12 |
2024-02-05 |
インサイト・ホールディングス・コーポレイション |
Lsd1阻害剤の塩
|
CN112656772B
(zh)
|
2015-10-15 |
2022-05-20 |
浙江东日药业有限公司 |
利伐沙班药物组合物
|
US9809541B2
(en)
|
2015-12-29 |
2017-11-07 |
Mirati Therapeutics, Inc. |
LSD1 inhibitors
|
WO2017130933A1
(ja)
|
2016-01-25 |
2017-08-03 |
国立大学法人熊本大学 |
神経変性疾患治療剤
|
ES2963148T3
(es)
|
2016-04-22 |
2024-03-25 |
Incyte Corp |
Formulaciones de un inhibidor de LSD1
|
US20200054643A1
(en)
|
2017-01-18 |
2020-02-20 |
Vanderbilt University |
Fused heterocyclic compounds as selective bmp inhibitors
|
UA125592C2
(uk)
|
2017-03-16 |
2022-04-27 |
Джянгсу Хенгруй Медісін Ко., Лтд. |
ПОХІДНА ГЕТЕРОАРИЛ[4,3-c]ПІРИМІДИН-5-АМІНУ, СПОСІБ ЇЇ ОТРИМАННЯ ТА ЇЇ МЕДИЧНІ ЗАСТОСУВАННЯ
|
JP7490631B2
(ja)
|
2018-07-05 |
2024-05-27 |
インサイト・コーポレイション |
A2a/a2b阻害剤としての縮合ピラジン誘導体
|
WO2020047198A1
(en)
|
2018-08-31 |
2020-03-05 |
Incyte Corporation |
Salts of an lsd1 inhibitor and processes for preparing the same
|